34753-27-0Relevant articles and documents
Design, synthesis and bioevaluation of 3-oxo-6-aryl-2,3-dihydropyridazine-4-carbohydrazide derivatives as novel xanthine oxidase inhibitors
Zhang, Lichao,Wang, Sibo,Yang, Mingzheng,Shi, Ailong,Wang, He,Guan, Qi,Bao, Kai,Zhang, Weige
, p. 1818 - 1823 (2019)
In view of expanding the structure activity relationship of xanthine oxidase inhibitors, a series of 3-oxo-6-aryl-2,3-dihydropyridazine-4-carbohydrazide/carboxylic acid derivatives were designed by molecular docking and synthesized. All the target compoun
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking
Ragusa, Giulio,Gómez-Ca?as, María,Morales, Paula,Rodríguez-Cueto, Carmen,Pazos, María R.,Asproni, Battistina,Cichero, Elena,Fossa, Paola,Pinna, Gerard A.,Jagerovic, Nadine,Fernández-Ruiz, Javier,Murineddu, Gabriele
, p. 398 - 412 (2017/01/16)
In the last few years, cannabinoid type-2 receptor (CB2R) selective ligands have shown a great potential as novel therapeutic drugs in several diseases. With the aim of discovering new selective cannabinoid ligands, a series of pyridazinone-4-c
3-Aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities
Wermuth,Schlewer,Bourguignon,Maghioros,Bouchet,Moire,Kan,Worms,Biziere
, p. 528 - 537 (2007/10/02)
Minaprine [3[(β-morpholinoethyl)amino]4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effe